PE20190732A1 - Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje - Google Patents
Compuestos y composiciones como inhibidores de los receptores endosomales tipo peajeInfo
- Publication number
- PE20190732A1 PE20190732A1 PE2019000478A PE2019000478A PE20190732A1 PE 20190732 A1 PE20190732 A1 PE 20190732A1 PE 2019000478 A PE2019000478 A PE 2019000478A PE 2019000478 A PE2019000478 A PE 2019000478A PE 20190732 A1 PE20190732 A1 PE 20190732A1
- Authority
- PE
- Peru
- Prior art keywords
- type
- methyl
- pyrazolo
- pyridin
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- ZWVCZRQPYARBEI-UHFFFAOYSA-N 4-[[3-methyl-5-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C1=C2C(=NC(=C1)C)NN=C2)CC12CCC(CC1)(CC2)N ZWVCZRQPYARBEI-UHFFFAOYSA-N 0.000 abstract 1
- XGRLHCCHDAZYII-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N)C XGRLHCCHDAZYII-UHFFFAOYSA-N 0.000 abstract 1
- RCPFKNIWFCVDLQ-UHFFFAOYSA-N 4-oxa-3-azabicyclo[3.2.1]octane Chemical compound C1C2CCC1ONC2 RCPFKNIWFCVDLQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 abstract 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 abstract 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 abstract 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 abstract 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 abstract 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385726P | 2016-09-09 | 2016-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190732A1 true PE20190732A1 (es) | 2019-05-23 |
Family
ID=60001955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000478A PE20190732A1 (es) | 2016-09-09 | 2017-09-06 | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10954233B2 ( ) |
| EP (2) | EP3510033B1 ( ) |
| JP (1) | JP6779371B2 ( ) |
| KR (2) | KR20190039809A ( ) |
| CN (2) | CN115215886A ( ) |
| AU (1) | AU2017323584C1 ( ) |
| BR (1) | BR112019004597A2 ( ) |
| CA (1) | CA3031585A1 ( ) |
| CL (1) | CL2019000588A1 ( ) |
| CO (1) | CO2019003397A2 ( ) |
| CR (1) | CR20190119A ( ) |
| CU (1) | CU24526B1 ( ) |
| CY (1) | CY1125007T1 ( ) |
| DK (1) | DK3510033T3 ( ) |
| DO (1) | DOP2019000055A ( ) |
| EA (1) | EA036880B1 ( ) |
| EC (1) | ECSP19024046A ( ) |
| ES (1) | ES2905981T3 ( ) |
| HR (1) | HRP20220144T1 ( ) |
| HU (1) | HUE057254T2 ( ) |
| IL (1) | IL265159B ( ) |
| JO (1) | JOP20190041B1 ( ) |
| LT (1) | LT3510033T ( ) |
| MA (1) | MA46196A ( ) |
| MX (1) | MX2019002797A ( ) |
| MY (1) | MY194813A ( ) |
| PE (1) | PE20190732A1 ( ) |
| PH (1) | PH12019500161A1 ( ) |
| PL (1) | PL3510033T3 ( ) |
| PT (1) | PT3510033T ( ) |
| RS (1) | RS62913B1 ( ) |
| RU (1) | RU2759678C2 ( ) |
| SG (1) | SG11201900482SA ( ) |
| SI (1) | SI3510033T1 ( ) |
| WO (1) | WO2018047081A1 ( ) |
| ZA (1) | ZA201900227B ( ) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62591B1 (sr) | 2013-09-24 | 2021-12-31 | Fujifilm Corp | Novo jedinjenje koje sadrži azot ili njegova so ili njihov kompleks sa metalom |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| PT3510033T (pt) | 2016-09-09 | 2022-02-18 | Novartis Ag | Compostos e composições como inibidores de recetores endossomais do tipo toll |
| DK3526323T3 (da) | 2016-10-14 | 2023-06-26 | Prec Biosciences Inc | Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| CA3084569A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP2021507889A (ja) | 2017-12-22 | 2021-02-25 | ノバルティス アーゲー | ピラゾロピペリジン誘導体の新規な使用 |
| CN111699187A (zh) | 2018-02-12 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的砜化合物和衍生物 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| EP3793998A1 (en) | 2018-05-18 | 2021-03-24 | Novartis AG | Crystalline forms of a tlr7/tlr8 inhibitor |
| US11713327B2 (en) | 2018-06-12 | 2023-08-01 | Hoffmann-La Roche Inc. | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN112638908A (zh) | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| CN112654618A (zh) | 2018-09-06 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型环脒化合物 |
| EP3847165A1 (en) * | 2018-09-07 | 2021-07-14 | F. Hoffmann-La Roche AG | Novel pyrrolidine amine compounds for the treatment of autoimmune disease |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TW202136260A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| AU2020231201A1 (en) | 2019-03-07 | 2021-08-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2020240272A1 (en) * | 2019-05-31 | 2020-12-03 | Dr.Reddy's Institute Of Life Sciences | Preparation of novel 1 h-pyrazolo[4,3-d]pyrimidines, their compositions, synthesis and methods of using them for treating tuberculosis |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| CN115835910A (zh) | 2020-07-14 | 2023-03-21 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢化异喹啉或氢化萘啶化合物 |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024520593A (ja) | 2021-06-23 | 2024-05-24 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AR127126A1 (es) | 2021-09-24 | 2023-12-20 | Hoffmann La Roche | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias |
| IL313846A (en) | 2022-01-11 | 2024-08-01 | Novartis Ag | Tlr7/8-antagonist for the treatment of sjögren's syndrome or mixed connective tissue disease |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100904157B1 (ko) | 2000-08-10 | 2009-06-23 | 파마시아 이탈리아 에스.피.에이. | 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물 |
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| WO2004080457A1 (en) | 2003-03-11 | 2004-09-23 | Pharmacia Italia S.P.A. | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| BRPI0517378A (pt) | 2004-10-27 | 2008-10-07 | Janssen Pharmaceutica Nv | moduladores de tetraidro piridinil pirazol canabinóide |
| MX2008002207A (es) * | 2005-08-16 | 2008-03-27 | Memory Pharm Corp | Inhibidores de fosfodiesterasa 10. |
| US20090118263A1 (en) * | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
| US20070254913A1 (en) | 2006-04-19 | 2007-11-01 | Dunn Robert F | Phosphodiesterase 4 inhibitors |
| US8093257B2 (en) | 2007-05-04 | 2012-01-10 | Bristol-Myers Squibb Company | [6,5]-bicyclic GPR119 G protein-coupled receptor agonists |
| JP5444239B2 (ja) * | 2007-11-02 | 2014-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体 |
| WO2011022509A2 (en) | 2009-08-18 | 2011-02-24 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| SI2491035T1 (sl) * | 2009-10-22 | 2017-10-30 | Gilead Sciences, Inc. | Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| WO2012154608A1 (en) | 2011-05-06 | 2012-11-15 | Intellikine, Llc | Reactive mtor and pi3 kinase inhibitors and uses thereof |
| CA2840060A1 (en) | 2011-06-27 | 2013-01-03 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| WO2013117615A1 (en) * | 2012-02-08 | 2013-08-15 | Janssen R&D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| WO2014034719A1 (ja) | 2012-08-29 | 2014-03-06 | 興和株式会社 | Ｔｌｒ阻害作用を有するキノリン誘導体 |
| HUE037064T2 (hu) | 2012-10-10 | 2018-08-28 | Janssen Sciences Ireland Uc | Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére |
| EP2945938B1 (en) | 2013-01-18 | 2018-03-07 | F. Hoffmann-La Roche AG | 3-substituted pyrazoles and use as dlk inhibitors |
| EA201591815A1 (ru) | 2013-03-14 | 2016-01-29 | Бристол-Майерс Сквибб Компани | Бицикло [2.2.2] кислоты - модуляторы gpr120 |
| JP6263606B2 (ja) | 2013-05-02 | 2018-01-17 | ファイザー・インク | Ｐｄｅ１０阻害剤としてのイミダゾ−トリアジン誘導体 |
| US10471139B2 (en) | 2013-08-15 | 2019-11-12 | The University Of Kansas | Toll-like receptor agonists |
| WO2015024021A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | Antibacterial compounds |
| SG11201601199QA (en) | 2013-08-19 | 2016-03-30 | Univ Kingston | Carbene-functionalized composite materials |
| WO2015025025A1 (en) | 2013-08-22 | 2015-02-26 | F. Hoffmann-La Roche Ag | Alkynyl alcohols and methods of use |
| WO2015036044A1 (en) | 2013-09-13 | 2015-03-19 | Telormedix Sa | Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood |
| JO3554B1 (ar) * | 2013-10-14 | 2020-07-05 | Eisai R&D Man Co Ltd | مركبات كينولين مستبدلة انتقائياً |
| MX363708B (es) | 2013-10-14 | 2019-03-29 | Eisai R&D Man Co Ltd | Compuestos de quinolina selectivamente sustituidos. |
| AR101106A1 (es) * | 2014-07-02 | 2016-11-23 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton |
| EP3190113B1 (en) | 2014-08-15 | 2021-05-19 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as tlr7 agonist |
| ES2746839T3 (es) * | 2014-12-18 | 2020-03-09 | Pfizer | Derivados de pirimidina y triazina y su uso como inhibidores de AXL |
| KR20170118706A (ko) | 2014-12-30 | 2017-10-25 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염 감염을 치료하는 유도체 및 그 방법 |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| ES2898635T3 (es) | 2015-03-12 | 2022-03-08 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| RS64261B1 (sr) | 2016-03-16 | 2023-07-31 | Kura Oncology Inc | Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe |
| PT3510033T (pt) | 2016-09-09 | 2022-02-18 | Novartis Ag | Compostos e composições como inibidores de recetores endossomais do tipo toll |
-
2017
- 2017-09-06 PT PT177779667T patent/PT3510033T/pt unknown
- 2017-09-06 AU AU2017323584A patent/AU2017323584C1/en active Active
- 2017-09-06 CU CU2019000018A patent/CU24526B1/es unknown
- 2017-09-06 CN CN202210863391.4A patent/CN115215886A/zh active Pending
- 2017-09-06 SI SI201731065T patent/SI3510033T1/sl unknown
- 2017-09-06 US US16/330,820 patent/US10954233B2/en active Active
- 2017-09-06 EP EP17777966.7A patent/EP3510033B1/en active Active
- 2017-09-06 PE PE2019000478A patent/PE20190732A1/es unknown
- 2017-09-06 EA EA201990657A patent/EA036880B1/ru not_active IP Right Cessation
- 2017-09-06 EP EP21208454.5A patent/EP4059934A1/en active Pending
- 2017-09-06 SG SG11201900482SA patent/SG11201900482SA/en unknown
- 2017-09-06 CN CN201780053304.6A patent/CN109641899B/zh active Active
- 2017-09-06 RS RS20220087A patent/RS62913B1/sr unknown
- 2017-09-06 WO PCT/IB2017/055375 patent/WO2018047081A1/en unknown
- 2017-09-06 MX MX2019002797A patent/MX2019002797A/es unknown
- 2017-09-06 MY MYPI2019000071A patent/MY194813A/en unknown
- 2017-09-06 KR KR1020197008484A patent/KR20190039809A/ko not_active IP Right Cessation
- 2017-09-06 LT LTEPPCT/IB2017/055375T patent/LT3510033T/lt unknown
- 2017-09-06 HR HRP20220144TT patent/HRP20220144T1/hr unknown
- 2017-09-06 BR BR112019004597A patent/BR112019004597A2/pt active Search and Examination
- 2017-09-06 DK DK17777966.7T patent/DK3510033T3/da active
- 2017-09-06 CR CR20190119A patent/CR20190119A/es unknown
- 2017-09-06 HU HUE17777966A patent/HUE057254T2/hu unknown
- 2017-09-06 RU RU2019110157A patent/RU2759678C2/ru active
- 2017-09-06 KR KR1020217018684A patent/KR102411532B1/ko active IP Right Grant
- 2017-09-06 ES ES17777966T patent/ES2905981T3/es active Active
- 2017-09-06 CA CA3031585A patent/CA3031585A1/en active Pending
- 2017-09-06 JO JOP/2019/0041A patent/JOP20190041B1/ar active
- 2017-09-06 MA MA046196A patent/MA46196A/fr unknown
- 2017-09-06 JP JP2019513008A patent/JP6779371B2/ja active Active
- 2017-09-06 PL PL17777966T patent/PL3510033T3/pl unknown
-
2019
- 2019-01-14 ZA ZA201900227A patent/ZA201900227B/en unknown
- 2019-01-22 PH PH12019500161A patent/PH12019500161A1/en unknown
- 2019-03-04 IL IL265159A patent/IL265159B/en unknown
- 2019-03-06 DO DO2019000055A patent/DOP2019000055A/es unknown
- 2019-03-08 CL CL2019000588A patent/CL2019000588A1/es unknown
- 2019-04-05 EC ECSENADI201924046A patent/ECSP19024046A/es unknown
- 2019-04-05 CO CONC2019/0003397A patent/CO2019003397A2/es unknown
-
2020
- 2020-12-16 US US17/124,346 patent/US20210101902A1/en not_active Abandoned
-
2022
- 2022-02-22 CY CY20221100153T patent/CY1125007T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190732A1 (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| AR127309A2 (es) | Derivados de piridazinona | |
| MX2018015422A (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridini lo. | |
| CO6241157A2 (es) | "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9" | |
| MX2020005873A (es) | Compuestos de 6-azaindol. | |
| AR102213A1 (es) | Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| UY35935A (es) | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 | |
| AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR063318A1 (es) | Pirazoliltienopiridinas terapeuticas | |
| AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
| AR078535A1 (es) | Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras | |
| RS54833B1 (sr) | Novi hiralni n-acil-5,6,7, (8-supstituisan)-tetrahidro-[1,2,4]triazolo [4,3-a]pirazini kao selektivni antagonisti nk-3 receptora, farmaceutsko jedinjenje, i postupci za upotrebu u nk-3 receptorom posredovanim poremećajima |